Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 142 of the 145 references it cites were found in a registry or an index; 20 of the 88 sources its claims cite were checked for support.

The Utility of Iron Chelators in the Management of Inflammatory Disorders

Open access

Abstract

Since iron can contribute to detrimental radical generating processes through the Fenton and Haber‐Weiss reactions, it seems to be a reasonable approach to modulate iron‐related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or increased baseline iron levels different consequences regarding protection or susceptibility to inflammation have to be considered. Given the role of iron in development of inflammatory diseases, pharmaceutical agents targeting this pathway promise to improve the clinical outcome. The objective of this review is to highlight the mechanisms of iron regulation and iron chelation, and to demonstrate the potential impact of this strategy in the management of several acute and chronic inflammatory diseases, including cancer.

Overview

CoChat Summary

TL;DR

This review argues that iron-catalyzed reactive oxygen species contribute to acute and chronic inflammatory diseases, and that iron chelators may offer therapeutic benefit by sequestering redox-active iron. It surveys experimental and clinical evidence across cancer, atherosclerosis, diabetes/obesity, renal fibrosis, glaucoma, SIRS, ischemia-reperfusion injury, colitis, anemia, and iron overload/deficiency contexts, while noting risks and the need for better chelators.

Key findings

  • Iron is essential but can catalyze ROS via Fenton and Haber-Weiss reactions; dysregulated iron homeostasis is linked to progressive inflammatory/degenerative diseases and cancer. The body contains approximately 3–4 g iron: hemoglobin accounts for 65%, ferritin/hemosiderin 25%, myoglobin/cytochromes/other enzymes 10%, and transferrin-bound iron about 0.1%; absorption is around 1 mg/day in men and 2 mg/day in women, and macrophage iron recycling is 20-fold greater than daily intestinal absorption.
  • Inflammation triggers hypoferremia/anemia of inflammation through cytokines such as IL-6 and hepcidin; hepcidin binds ferroportin, causing its internalization and degradation, trapping iron in macrophages and hepatocytes and inhibiting intestinal iron absorption.
  • Chelation studies report benefits in models: deferoxamine reduced adiposity via oxidative stress and inflammation in obese/type 2 diabetes KKAy mice, with only mild but not significant reductions in hemoglobin and hematocrit after two weeks; in UUO mice, deferoxamine reduced fibrotic progression, interstitial macrophage infiltration, IL-1β and MCP-1 expression, and myofibroblast accumulation; in pigs, deferoxamine attenuated lipid peroxidation, inhibited IL-6, and diminished SIRS and MOD; in rat colitis, highest-dose maltol was comparable to prednisolone and to deferoxamine/deferiprone.
  • Clinical/contextual evidence notes that iron overload in hemochromatosis and thalassemia increases susceptibility to infections; the Pemba trial led to adverse events in children receiving iron in a malaria-endemic region; and in tuberculosis, iron supplementation increased mycobacterial growth and morbidity/mortality. New chelators designed to hold iron in a non-redox-active state may improve efficacy, whereas conventional chelators can be utilized by pathogens as iron sources.

Methods

  • Narrative review whose objective was to highlight mechanisms of iron regulation and iron chelation and to demonstrate the potential impact of this strategy in several acute and chronic inflammatory diseases, including cancer.
  • Data source: literature regarding experimental and clinical evidence for iron-related anti-inflammatory strategies; no primary patient cohort or systematic search strategy is described.
  • Main analysis: qualitative synthesis of mechanistic pathways and disease-specific studies covering cancer, atherosclerosis, diabetes/obesity, renal fibrosis, glaucoma, SIRS, ischemia-reperfusion injury, colitis, anemia of inflammation, hereditary/acquired iron overload, and iron deficiency.

Limitations

  • Stated: iron depletion as therapy is controversial because stored iron is often assumed to be inherently safe; the benefit of iron depletion can only be rigorously demonstrated in relation to iron in excess of needs; appropriate trials to rule out potential hazards of iron stores have not been undertaken; short-term harm such as anemia is possible; and conventional chelators may promote infection or be utilized by pathogens.
  • Evident: as a narrative review, there is no systematic search, risk-of-bias assessment, or meta-analysis, and many experimental findings come from animal models while clinical evidence remains limited or observational.
  • Evident: no primary data or sample size are reported, so efficacy conclusions are synthesized from heterogeneous studies rather than tested in a single controlled trial.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1155/2015/516740

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Role of iron in the development of disease.
Figure 1 Role of iron in the development of disease.CC BY · PubMed Central
Figure 2 Putative involvement of iron in inflammation. Inflammation induces the production of proinflammatory cytokines which can induce the sequestration of iron within cells through the modulation of iron regulatory protein expression (e.g., divalent metal transporter 1 (DMT1), hepcidin (HAMP), ferritin, and ferroportin1 (FPN)). Increased iron levels, especially in macrophages, may lead to ROS production via the Fenton and Haber-Weiss reactions. ROS in return can increase levels of labile iron and induce oxidative damage of DNA, proteins, and lipids. Additionally, ROS can activate redox-sensitive transcription factors whose targets include proinflammatory cytokines.
Figure 2 Putative involvement of iron in inflammation. Inflammation induces the production of proinflammatory cytokines which can induce the sequestration of iron within cells through the modulation of iron regulatory protein expression (e.g., divalent metal transporter 1 (DMT1), hepcidin (HAMP), ferritin, and ferroportin1 (FPN)). Increased iron levels, especially in macrophages, may lead to ROS production via the Fenton and Haber-Weiss reactions. ROS in return can increase levels of labile iron and induce oxidative damage of DNA, proteins, and lipids. Additionally, ROS can activate redox-sensitive transcription factors whose targets include proinflammatory cytokines.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 4 Not valid · 49 Not checked · 13 Own results and interpretations

39 more claims · 6 with their cited sources checked

Create a free account to see all 79 claims and to verify the 68 references still open.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 145 references

Cited by

See all 55

Metadata

Authors
Lehmann, C., Islam, S., Jarosch, S., Zhou, J., Hoskin, D., Greenshields, A., Al-Banna, N., Sharawy, N., Sczcesniak, A., Kelly, M., Wafa, K., Cheliak, W., & Holbein, B.
Affiliations
Dalhousie University (CA)
Corresponding author
Lehmann, C.
Venue
Mediators of Inflammation
Publisher
Wiley
Published
2015-01
Volume
2015
Issue
1
Pages
516740-516740
ISSN
  • 0962-9351 (ISSN-L)
  • 1466-1861
OpenAlex
W1974910643
Cited by
54
References
145
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 10 · 2019: 6 · 2018: 4 · 2017: 1 · 2016: 5
FWCI
0.50
Type
journal article
Language
en
Open access
Locations
  • Mediators of Inflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
Keywords
iron chelators, iron regulation, inflammation, Fenton reaction, Haber-Weiss reaction, iron availability, oxidative stress, chronic inflammatory diseases, acute inflammatory diseases, cancer
MeSH terms
Animals, Fibrosis, Hemochromatosis, Humans, Inflammation, Iron, Iron Chelating Agents, Kidney, Neoplasms, Reactive Oxygen Species, Systemic Inflammatory Response Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Utility of Iron Chelators in the Management of Inflammatory Disorders. https://app.cochat.ai/papers/10.1155/2015/516740
The paper
Lehmann, C., Islam, S., Jarosch, S., Zhou, J., Hoskin, D., Greenshields, A., Al-Banna, N., Sharawy, N., Sczcesniak, A., Kelly, M., Wafa, K., Cheliak, W., & Holbein, B. (2015). The Utility of Iron Chelators in the Management of Inflammatory Disorders. Mediators of Inflammation. https://doi.org/10.1155/2015/516740

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.